IMMUTEP LIMITED (IMM)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:

IMM - IMMUTEP LIMITED
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.05
Index: ALL-ORDS
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.315
26 May |
OPEN $0.35 |
HIGH $0.36 |
7,676,073 LOW $0.30 |
TARGET | |||||
|
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGH . AHZ . ANP . ARX . AVH . BIO . BNO . BOT . CAU . CSL . CUV . EOF . FTT . GSS . HXL . IDT . IMU . IVX . KZA . LGP . MAP . MDC . MSB . MVP . MXC . MYX . NEU . NXS . OCC . OPT . OSL . PAL . PAR . PBP . PNV . PXS . PYC . RAC . RCE . RNO . SPL . TFC . TIS . TLX . TRP . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY21 Actual |
FY22 Actual |
FY23 Forecast |
FY24 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | - 3.8 | - 4.8 | xxx |
DPS (cps) | xxx | N/A | 0.0 | xxx |
EPS Growth | xxx | N/A | N/A | xxx |
DPS Growth | xxx | N/A | N/A | xxx |
PE Ratio | xxx | N/A | N/A | xxx |
Dividend Yield | xxx | N/A | 0.0% | xxx |
Div Pay Ratio(%) | xxx | N/A | N/A | xxx |
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -3.8 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 0.2 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 10.9 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -30.2 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -18,906.51 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -38.50 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -37.56 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -34.97 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -38.50 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -44.66 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -30.3 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 0 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 80 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 2.67 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 0.0 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 13.45 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 2 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 36 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 25 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
IMM STOCK CHART

FNArena News on IMM
1 |
Australian Broker Call *Extra* Edition – May 23, 2023May 23 2023 - Daily Market Reports |
2 |
Australian Broker Call *Extra* Edition – May 08, 2023May 08 2023 - Daily Market Reports |
3 |
Rudi’s View: Domino’s Pizza, Newcrest & QantasMar 17 2023 - Rudi's View |
4 |
Rudi’s View: CSL, Mineral Resources, Ridley & ReadyTechFeb 03 2023 - Rudi's View |
5 |
Rudi’s View: Telix, Telstra, Treasury Wine & MoreJan 19 2023 - Rudi's View |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
Dr Boreham’s Crucible: Chimeric TherapeuticsMay 26 2023 - Small Caps |
2 |
Avita Medical Preps For Enlarged US OpportunityMay 17 2023 - Small Caps |
3 |
Dr Boreham’s Crucible: Radiopharm TheronosticsApr 13 2023 - Small Caps |
4 |
Dr Boreham’s Crucible: Avita MedicalMar 29 2023 - Small Caps |
5 |
Telix Pharmaceuticals’ Pipeline Full Of PromiseMar 21 2023 - Small Caps |
6 |
FDA Approval Puts Rocket Under Neuren SharesMar 16 2023 - Small Caps |
7 |
Dr Boreham’s Crucible: Actinogen MedicalNov 30 2022 - Small Caps |
8 |
Dr Boreham’s Crucible: Qbiotics GroupNov 09 2022 - Small Caps |
9 |
Dr Boreham’s Crucible: PharmaxisOct 05 2022 - Small Caps |
10 |
Brokers Review Prospects For CSLSep 30 2022 - Australia |